{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:56:38Z","timestamp":1790200598491,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Staff Fund at Yale New Haven Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Xylazine prevalence has surged in the unregulated fentanyl supply across the United States. In efforts to inform education initiatives for people who use drugs, this study aimed to identify factors associated with reported xylazine use and knowledge gaps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Connecticut-based mixed methods study employed both surveys and interviews. Survey participants, recruited from collaborating harm reduction organizations, were adults who used unregulated substances in the last six months. They were asked about their drug use, knowledge of xylazine, service use experience, and demographic information. Purposive sampling of survey participants was then used to select individuals for in-depth interviews. Topic guides were designed to gain a deeper understanding of participants\u2019 xylazine awareness and future learning preferences. Quantitative data were dichotomized based on reported xylazine use and analyzed using descriptive statistics, Chi-square, Fisher\u2019s exact, or t-tests. Simple and multiple logistic regression were used to find correlates of reported use of xylazine. Interviews were analyzed using thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between August and November 2024, we surveyed 114 respondents. Nearly half reported lifetime xylazine use (49.1%) and almost three-quarters heard of xylazine prior to engaging in the study (71.9%). Multiple logistic regression revealed that unemployment (OR 6.5, 95% CI 2.4\u201317.8), past-year fentanyl use (OR 41.1, 95% CI 4.8\u2013354.4), and harm reduction service engagement (OR 5.2, 95% CI 1.6\u201316.8) as predictors of reported xylazine use, after adjustments. We conducted n=31 interviews; thematic analysis identified four major themes: (1) information about xylazine was obtained from many sources, (2) knowledge about xylazine was gained from using xylazine, (3) some misconceptions about xylazine have developed, and (4) multiple mechanisms for xylazine education are desired.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study underscores the need for accessible xylazine education to address knowledge and confidence gaps among people who use drugs. Xylazine education should be tailored to one\u2019s likely xylazine exposure. Education must be harm-reduction oriented, stigma-free, and incorporate the voices of people who use drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-026-01437-7","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:24:27Z","timestamp":1775222667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Zeroing in on xylazine - a mixed methods study to explore correlates of reported xylazine use and educational gaps among people who use drugs"],"prefix":"10.1186","volume":"23","author":[{"given":"Katherine","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Minahan-Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Biegacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Heimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Sue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"8","key":"1437_CR1","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","volume":"112","author":"RS Alexander","year":"2022","unstructured":"Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212\u20136.","journal-title":"Am J Public Health"},{"issue":"26","key":"1437_CR2","doi-asserted-by":"publisher","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","volume":"72","author":"M Kariisa","year":"2023","unstructured":"Kariisa M, O\u2019Donnell J, Kumar S, Mattson CL, Goldberger BA. Illicitly manufactured Fentanyl\u2013involved overdose deaths with detected Xylazine\u2014United States, January 2019\u2013June 2022. MMWR Morb Mortal Wkly Rep. 2023;72(26):721\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"1437_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0165-5728(00)00370-2","volume":"113","author":"V \u0106upi\u0107","year":"2001","unstructured":"\u0106upi\u0107 V, \u010coli\u0107 M, Pavi\u010di\u0107 L, Vu\u010devi\u0107 D, Varagi\u0107 VM. Immunomodulatory effect of Xylazine, an \u03b12 adrenergic agonist, on rat spleen cells in culture. J Neuroimmunol. 2001;113(1):19\u201329.","journal-title":"J Neuroimmunol"},{"issue":"8","key":"1437_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jat\/bkac049","volume":"46","author":"SL Kacinko","year":"2022","unstructured":"Kacinko SL, Mohr ALA, Logan BK, Barbieri EJ. Xylazine: pharmacology review and prevalence and drug combinations in forensic toxicology casework. J Anal Toxicol. 2022;46(8):911\u20137.","journal-title":"J Anal Toxicol"},{"key":"1437_CR5","unstructured":"DEA. DEA Joint Intelligence Report: The Growing Threat of Xylazine and its Mixture with Illicit Drugs [Internet]. 2022 Oct. Available from: https:\/\/www.dea.gov\/sites\/default\/files\/2022-12\/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf"},{"issue":"4","key":"1437_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2885.1988.tb00189.x","volume":"11","author":"SA Greene","year":"1988","unstructured":"Greene SA, Thurmon JC. Xylazine\u2014a review of its pharmacology and use in veterinary medicine. Vet Pharmacol Ther. 1988;11(4):295\u2013313.","journal-title":"Vet Pharmacol Ther"},{"key":"1437_CR7","doi-asserted-by":"crossref","unstructured":"Ayub S, Parnia S, Poddar K, Bachu AK, Sullivan A, Khan AM, et al. Xylazine in the Opioid Epidemic: A Systematic Review of Case Reports and Clinical Implications. Cureus [Internet]. 2023 Mar 29 [cited 2023 Sep 19]; Available from: https:\/\/www.cureus.com\/articles\/146922-xylazine-in-the-opioid-epidemic-a-systematic-review-of-case-reports-and-clinical-implications","DOI":"10.7759\/cureus.36864"},{"issue":"7","key":"1437_CR8","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","volume":"240","author":"S Choi","year":"2023","unstructured":"Choi S, Irwin MR, Kiyatkin EA. Xylazine effects on opioid-induced brain hypoxia. Psychopharmacology Berl. 2023;240(7):1561\u201371.","journal-title":"Psychopharmacology Berl"},{"issue":"3","key":"1437_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/15563650.2022.2159427","volume":"61","author":"JS Love","year":"2023","unstructured":"Love JS, Levine M, Aldy K, Brent J, Krotulski AJ, Logan BK, et al. Opioid overdoses involving Xylazine in emergency department patients: a multicenter study. Clin Toxicol Phila. 2023;61(3):173\u201380 (Mar 4;).","journal-title":"Clin Toxicol Phila"},{"issue":"1","key":"1437_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12954-023-00879-7","volume":"20","author":"CM Zagorski","year":"2023","unstructured":"Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20(1):141.","journal-title":"Harm Reduct J."},{"issue":"1","key":"1437_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-01052-4","volume":"21","author":"K Hill","year":"2024","unstructured":"Hill K, Minahan-Rowley R, Biegacki ET, Heimer R, Sue KL. Providers\u2019 knowledge and perception of Xylazine in the unregulated drug supply: a sequential explanatory mixed-methods study. Harm Reduct J. 2024;21(1):148.","journal-title":"Harm Reduct J"},{"key":"1437_CR12","unstructured":"CTDPH. Connecticut Department of Public Health Drug Overdose Monthly Report [Internet]. Available from: https:\/\/portal.ct.gov\/-\/media\/DPH\/Injury-and-Violence-Prevention\/Opioid-Overdose-Data\/Monthly-Death-Reports\/2019-March-2023_Drug-Overdose-Deaths-Monthly-Report_Connecticut_updated-on-4-18-2023_Final.pdf"},{"key":"1437_CR13","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.15585\/mmwr.mm7037a5","volume":"70","author":"S Thangada","year":"2021","unstructured":"Thangada S, Clinton H, Ali S. Notes from the field: Xylazine, a veterinary tranquilizer, identified as an emerging novel substance in drug overdose deaths\u2014Connecticut, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70:1303\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1437_CR14","doi-asserted-by":"publisher","unstructured":"Dowton A, Doernberg M, Heiman E, Barelli P, Golden M, Wang H, et al. Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut. J Addict Med [Internet]. 2023 Jun 28 [cited 2023 Sep 19];Publish Ahead of Print. Available from: https:\/\/journals.lww.com\/https:\/\/doi.org\/10.1097\/ADM.0000000000001198","DOI":"10.1097\/ADM.0000000000001198"},{"key":"1437_CR15","doi-asserted-by":"crossref","unstructured":"Sue KL, Hawk K. Clinical considerations for the management of xylazine overdoses and xylazine\u2010related wounds. Addiction. 2023 Nov 8;add.16388.","DOI":"10.1111\/add.16388"},{"key":"1437_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104154","volume":"120","author":"T Quijano","year":"2023","unstructured":"Quijano T, Crowell J, Eggert K, Clark K, Alexander M, Grau L, et al. Xylazine in the drug supply: emerging threats and lessons learned in areas with high levels of adulteration. Int J Drug Policy. 2023;120:104154.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1437_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"14","key":"1437_CR18","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1080\/10826084.2024.2393220","volume":"59","author":"AV Thuillier","year":"2024","unstructured":"Thuillier AV, Qiao Y, Wu ZH. Modeling changes of fatal xylazine-involved drug overdoses in connecticut across time. Subst Use Misuse. 2024;59(14):2103\u201311.","journal-title":"Subst Use Misuse."},{"issue":"1","key":"1437_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. \u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53.","journal-title":"Harm Reduct J"},{"key":"1437_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"1437_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108589","volume":"221","author":"C Fong","year":"2021","unstructured":"Fong C, Mateu-Gelabert P, Ciervo C, Eckhardt B, Aponte-Melendez Y, Kapadia S, et al. Medical provider stigma experienced by people who use drugs (MPS-PWUD): development and validation of a scale among people who currently inject drugs in New York City. Drug Alcohol Depend. 2021;221:108589.","journal-title":"Drug Alcohol Depend"},{"key":"1437_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","volume":"57","author":"CE Paquette","year":"2018","unstructured":"Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104\u201310.","journal-title":"Int J Drug Policy"},{"key":"1437_CR23","doi-asserted-by":"publisher","unstructured":"McFadden R, Wallace-Keeshen S, Petrillo Straub K, Hosey RA, Neuschatz R, McNulty K, et al. Xylazine-associated Wounds: Clinical Experience From a Low-barrier Wound Care Clinic in Philadelphia. J Addict Med [Internet]. 2023 Nov 29 [cited 2023 Dec 4]; Available from: https:\/\/journals.lww.com\/https:\/\/doi.org\/10.1097\/ADM.0000000000001245","DOI":"10.1097\/ADM.0000000000001245"},{"key":"1437_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.112390","volume":"263","author":"R Jawa","year":"2024","unstructured":"Jawa R, Ismail S, Shang M, Murray S, Murray-Krezan C, Zheng Y, et al. Drug use practices and wound care experiences in the age of Xylazine adulteration. Drug Alcohol Depend. 2024;263:112390.","journal-title":"Drug Alcohol Depend"},{"key":"1437_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104338","volume":"125","author":"JM Bowles","year":"2024","unstructured":"Bowles JM, Copulsky EC, Reed MK. Media framing Xylazine as a \u201czombie drug\u201d is amplifying stigma onto people who use drugs. Int J Drug Policy. 2024;125:104338.","journal-title":"Int J Drug Policy"},{"key":"1437_CR26","doi-asserted-by":"publisher","unstructured":"Jawa R, Goswami M, Ismail S, Shang M, McMurtrie G, Murray S, et al. A Content Analysis of Xylazine-associated Stigma in Web-based Media Driven by the Zombie Term and Stigmatizing Imagery. Journal of Addiction Medicine [Internet]. 2025 May 14 [cited 2025 Jul 10]; Available from: https:\/\/journals.lww.com\/https:\/\/doi.org\/10.1097\/ADM.0000000000001506","DOI":"10.1097\/ADM.0000000000001506"},{"key":"1437_CR27","first-page":"297673422412651","volume":"3","author":"S Shrestha","year":"2024","unstructured":"Shrestha S, Cyr K, Hajinazarian G, Dillon J, Oh T, Pustz J, et al. Exploring xylazine awareness, health impacts, and harm reduction strategies: findings from a multimethods study in lowell massachusetts. Subst Use Addict J. 2024;3:29767342241265180.","journal-title":"Subst Use Addict J"},{"issue":"1","key":"1437_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12954-024-01097-5","volume":"21","author":"NL Michaels","year":"2024","unstructured":"Michaels NL, Bista S, Short Mejia A, Hays H, Smith GA. Xylazine awareness and attitudes among people who use drugs in Ohio, 2023\u20132024. Harm Reduct J. 2024;21(1):182.","journal-title":"Harm Reduct J."},{"issue":"2","key":"1437_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0572","volume":"7","author":"M Hochheimer","year":"2024","unstructured":"Hochheimer M, Strickland JC, Rabinowitz JA, Ellis JD, Dunn KE, Huhn AS. Knowledge, preference, and adverse effects of xylazine among adults in substance use treatment. JAMA Netw Open. 2024;7(2):e240572.","journal-title":"JAMA Netw Open"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01437-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:11:28Z","timestamp":1778717488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01437-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01437-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and all materials were approved by Yale Institutional Review Board (Protocol #2000036264). Participants engaged in our study voluntarily and provided informed consent prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}